Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 301 to 325 of 325

Guidance and quality standards awaiting development
Title	Type
Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772	Technology appraisal guidance
Troriluzole for spinocerebellar ataxia ID 6456	Technology appraisal guidance
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]	Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781	Technology appraisal guidance
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]	Technology appraisal guidance
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468	Technology appraisal guidance
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]	Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults	Interventional procedures guidance
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]	Technology appraisal guidance
Vilobelimab for treating COVID 19 TS ID 11815	Technology appraisal guidance
Virtual Wards for COPD exacerbations	Medical technologies guidance
Virtual Wards for Heart Failure	Medical technologies guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
Vosoritide for treating achondroplasia in people 4 months and over ID6488	Technology appraisal guidance
Vulnerable populations: strategies for tackling inequalities	Quality standard
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467	Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477	Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]	Technology appraisal guidance
Zavegepant for treating acute migraine TSID 11998	Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]	Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040	Technology appraisal guidance

Results per page

10
25
50
All